<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Enoxacin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00467</strong>&#160; (APRD00947)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00467/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00467/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00467.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00467.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00467.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00467.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00467.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00467">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Enoxacin</td><td>German</td><td>INN</td></tr><tr><td>Enoxacina</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>&#201;noxacine</td><td>French</td><td>INN</td></tr><tr><td>Enoxacino</td><td>Spanish</td><td>INN</td></tr><tr><td>Enoxacinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Almitil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bactidan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Comprecin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Enoksetin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Enoxen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Enoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Enoxor</td><td>Pierre Fabre</td></tr><tr><td>Enoxor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Enroxil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Flumark</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gyramid</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Penetrex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vinone</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>74011-58-8</td></tr><tr><th>Weight</th><td>Average: 320.3189<br>Monoisotopic: 320.128468635</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>IDYZIJYBMGIQMJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Naphthyridine Carboxylic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Naphthyridine Carboxylic Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Fluoroquinolones; Pyridinylpiperazines; Pyridinecarboxylic Acids; Aminopyridines and Derivatives; Diazinanes; Aryl Fluorides; Tertiary Amines; Enolates; Dialkylamines; Polyamines; Carboxylic Acids; Organofluorides</td></tr><tr><th>Substituents</th><td>pyridine carboxylic acid; pyridine carboxylic acid or derivative; aminopyridine; 1,4-diazinane; piperazine; pyridine; aryl halide; aryl fluoride; tertiary amine; polyamine; enolate; secondary amine; secondary aliphatic amine; carboxylic acid derivative; carboxylic acid; organohalogen; organofluoride; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of adults (&#8805;18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to <i>Neisseria gonorrhoeae</i>, (2) uncomplicated urinary tract infections (cystitis) due to <i>Escherichia coli</i>, <i>Staphylococcus epidermidis</i>, or <i>Staphylococcus saprophyticus</i>, and (3) complicated urinary tract infections due to <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, <i>Pseudomonas aeruginosa</i>, <i>Staphylococcus epidermidis</i>, or <i>Enterobacter cloacae</i>.</td></tr><tr><th>Pharmacodynamics</th><td>Enoxacin is a quinolone/fluoroquinolone antibiotic. Enoxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Enoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Enoxacin may be active against pathogens resistant to drugs that act by different mechanisms.</td></tr><tr><th>Mechanism of action</th><td>Enoxacin exerts its bactericidal action via the inhibition of the essential bacterial enzyme DNA gyrase (DNA Topoisomerase II).</td></tr><tr><th>Absorption</th><td>Rapidly absorbed following oral administration, with an absolute oral bioavailability of approximately 90%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Enoxacin is approximately 40% bound to plasma proteins in healthy subjects and is approximately 14% bound to plasma proteins in patients with impaired renal function.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Some isozymes of the cytochrome P-450 hepatic microsomal enzyme system are inhibited by enoxacin. After a single dose, greater than 40% was recovered in urine by 48 hours as unchanged drug.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Plasma half-life is 3 to 6 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.995</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8683</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8978</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8606</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7736</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8078</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7557</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8862</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5351</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9124
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.802
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8383 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6527
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5448
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Enoxacin may increase the effect of aminophylline.</td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. </td></tr><tr><td><a href="/drugs/DB00736">Esomeprazole</a></td><td>Esomeprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB00927">Famotidine</a></td><td>Famotidine may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB00893">Iron Dextran</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00448">Lansoprazole</a></td><td>Lansoprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB01378">Magnesium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00585">Nizatidine</a></td><td>Nizatidine may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Enoxacin may increase the effect of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB00213">Pantoprazole</a></td><td>Pantoprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB01129">Rabeprazole</a></td><td>Rabeprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Enoxacin increases levels/toxicity of ramelteon</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Enoxacin may increase the effect of theophylline.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>